|
|
Article: Duke Clinical Research Institute and PharmaNetics Sign Collaborative Agreement to Expand Use of Theranostic Tests.
- Article from:
- Business Wire
- Article date:
- December 7, 1999
CopyrightCOPYRIGHT 1999 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RALEIGH, N.C.--(BW HealthWire)--Dec. 7, 1999--
PharmaNetics, Inc. (NASDAQ NM: PHAR), the holding company of Cardiovascular Diagnostics, Inc., today announced that the Company has signed a two-year agreement with Duke Clinical Research Institute ("DCRI"), a subsidiary of the Duke Medical Center ("Duke"), making PharmaNetics the preferred provider of rapid point-of-care technology for anticoagulant compounds used in clinical trials at the DCRI. Duke also will collaborate with the Company to investigate additional applications of the Thrombolytic Assessment System (TAS) in managing new therapies. For certain indications and therapeutics, managing anticoagulation can ...